Dr Lal Pathlabs

Dr Lal PathLabs expands advanced diagnostics portfolio with genomics buy

The ₹168 crore acquisition of a 70 per cent stake in SN Genelab is expected to strengthen Dr Lal's genomics expertise and broaden its advanced diagnostics portfolio

Robust demand, stable pricing to keep diagnostics volumes strong in FY27

Brokerages expect diagnostic majors to sustain volume growth through FY27, aided by robust demand and stable pricing, though the recent stock rally may cap upside

Robust demand, pricing to keep volumes strong for diagnostics sector

Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage

Robust demand, pricing to keep volumes strong for diagnostics sector

Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage

DCB Bank, Dr Lal Path among Kotak Securities' top tech ideas; here's why

Geographically, DCB has a diversified pan-India presence with a stronger footprint across western and southern India, while continuing to expand selectively into underpenetrated markets.

Dr Lal Path jumps 8% to 52-week high on Q1 beat; up to 25% upside on cards

Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of ₹1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.

Dr Lal PathLabs jumps 5% after Q1 PAT surges 21%; ₹5 dividend declared

Dr Lal PathLabs' consolidated net profit grew by 21.4 per cent Y-o-Y to ₹170 crore in Q1 of FY27.

Dr Lal PathLabs soars 11%, hits 52-week high on huge volumes; here's why

Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.

Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%

Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.

Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive

Dr. Lal PathLabs recorded a 16.6 per cent Y-o-Y rise in revenue from operations to ₹702 crore in Q4 FY26 from ₹659.8 crore in the year-ago period

Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%

Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix

Dr Lal Path Labs Q4 FY26 results: Profit down 15.5%, revenue up 16.6%

Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier

Dr Lal back on the acquisition trail, tests South India for opportunities

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

Dr Lal back on the acquisition trail, tests South India for opportunities

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact

Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion

Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares

Preventive, precision testing spurs a bigger dose of diagnostics chains

Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India

Stocks gaining momentum? Here's why Escorts, Hudco, 3 others are on radar

Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%